$NXL

Nexalin Technology, Inc. (NXL): Entry into a Material Definitive Agreement

Nexalin Technology, Inc. (NXL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 21, 2026, Nexalin Technology, Inc. (the “Company”) entered into a Note Purchase Agreement (the “Note Purchase Agreement”) with an institutional investor (the “Investor”), pursuant to which the Investor purchased from

Original reporting
Published Aug 21, 2026, 9:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 9:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$NXL
Neutral
high confidence
Mentioned
$NXL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NXLNeutralLow
01

Why it matters

The financing provides short‑term liquidity but is unlikely to move the stock materially.

02

Market read

Primary disclosure of a small debt raise; limited trading relevance.

03

What to watch

Potential covenant restrictions or future financing needs not disclosed.

Relevance 6/10Novelty 6/10Timing: filed Aug 21 2026

Background

Nexalin Technology filed an 8‑K detailing a material definitive agreement for a promissory note.

Company-level read

Ticker impact

$NXLNeutralHigh confidence
Context

SEC 8‑K reports Nexalin Technology issuing a $1.17 M unsecured promissory note to Streeterville Capital.

Expected impact

little to no short‑term movement, potential slight upside if debt improves liquidity.

Evidence & confidence

Small unsecured note, modest size relative to market cap, no change to capital structure.

Market effects

None significant; debt issuance typical for micro‑caps.

No regional effect.

Minimal.

Counterpoint

If the note includes favorable terms, it could signal confidence and support a modest rally.

Key entities

  • Nexalin Technology, Inc.

    Issuer of the promissory note.

  • Streeterville Capital, LLC

    Purchaser of the note.

Related articles

$MUMedAI 8/10

Dow Falls Over 200 Points; Micron Earnings Top Views

U.S. stocks fell Thursday, with the Dow Jones dropping 200 points. Micron (MU) reported Q4 revenue of $54.23B, beating estimates. Nexalin (NXL) and Stablecoin (SDEV) shares surged, while Corteva (CTVA) and NewGenIvf (NIVF) shares declined. Oil and gold prices rose, while European and Asian markets closed mixed.

$NXLMed

Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in its Transition Toward Commercial Revenue Generation

Nexalin Technology (NXL) signed a 10-year exclusive distribution agreement with Inovanexa Medical Technologies for Brazil and six other South American countries. The deal includes a 100-device commercialization program, local manufacturing, and revenue-sharing. Nexalin Sync, approved for anxiety, depression, and insomnia, will be distributed across 300 million people.

$ANIXMedAI 8/10

RedChip Companies, Inc.: Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV

RedChip Companies will air interviews with Anixa Biosciences (NASDAQ:ANIX) and Nexalin Technology (NASDAQ:NXL) on Bloomberg TV and CNBC. Anixa is developing a breast cancer vaccine, while Nexalin focuses on neurostimulation for mental health. Both companies are preparing for key trials and commercialization efforts.

$NXLMedAI 8/10

Nexalin's Neurostimulation Trial Shows 77.8% Anxiety Response Rate In Brazil; Stock Up

Nexalin Technology (NXL) reported positive eight-week clinical trial results for its non-invasive DIFS neurostimulation in adults with generalized anxiety disorder and comorbid insomnia. Conducted at the University of São Paulo’s Institute of Psychiatry, the study used a 15 mA, 77.5 Hz protocol across 20 40-minute sessions. Nexalin said the end-of-treatment anxiety response rate was 77.8% (HAM-A drop by Session 5 and maintained at follow-up), with no serious adverse events.

$ADRXMedAI 9/10

ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offering

ADARx Pharmaceuticals (ADRX) announced the closing of an additional 3.94 million shares sold in its IPO, raising $513.2 million at $17 per share. Including a concurrent private placement, total gross proceeds reached $602.5 million. J.P. Morgan, Morgan Stanley, and others acted as underwriters.